In Japan, failing a drug quality audit can result in severe penalties, including fines, suspension of manufacturing licenses, and product recalls. Companies may face increased scrutiny, reputational damage, and potential legal action. Regulatory authorities may also impose corrective action plans to ensure compliance with pharmaceutical standards and safeguard public health.